

## CLINICAL UPDATE

<b>Brand Name</b>	Xpovio®
<b>Generic Name</b>	selinexor
<b>Drug Manufacturer</b>	Karyopharm Therapeutics Inc.

### Clinical Update

#### TYPE OF CLINICAL UPDATE

New Strengths (40 mg, 50 mg, 60 mg)

#### FDA APPROVAL DATE

April 15, 2021

#### LAUNCH DATE

June 03, 2021

#### REVIEW DESIGNATION

N/A

#### TYPE OF REVIEW

N/A

#### DISPENSING RESTRICTIONS

Specialty Pharmacy

### Overview

#### INDICATION(S) FOR USE

Xpovio® is a nuclear export inhibitor indicated:

- In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
- In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
- For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.

#### MECHANISMS OF ACTION

Xpovio® is a first-in-class SINE (Selective Inhibitor of Nuclear Export) compound. The drug inhibits chromosomal maintenance protein exportin 1 (XPO1), a nuclear export protein that mediates the transport of more than 200 cargo proteins, including most tumor-suppressor proteins. Xpovio® works to block the export process by binding to other proteins within the nucleus of the cell and shuttling them through the nuclear pores into the cytoplasm in the rest of the cell.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.

## CLINICAL UPDATE

### DOSAGE FORM(S) AND STRENGTH(S)

Tablets: 20 mg, 40 mg, 50 mg, 60 mg

### DOSE & ADMINISTRATION

- Multiple Myeloma in combination with Bortezomib and Dexamethasone (SvD): Recommended dosage of Xpovio® is 100 mg taken orally once weekly in combination with bortezomib and dexamethasone.
- Multiple Myeloma in Combination with Dexamethasone (Sd): Recommended dosage of Xpovio® is 80 mg taken orally on Days 1 and 3 of each week in combination with dexamethasone.
- DLBCL: Recommended dosage of Xpovio® is 60 mg taken orally on Days 1 and 3 of each week.

### EFFICACY

There is no change to the efficacy profile with the additions of the new strengths and additional package sizes.